Sutykine 12.5 mg Capsule
$5.24
$4.45
Sutykine 12.5 mg capsules are an essential treatment option for various cancers, including pancreatic cancer, gastrointestinal stromal tumors, and renal cell carcinoma. This targeted anticancer medication functions by inhibiting the proliferation of malignant cells, thereby helping to manage the disease effectively. Patients taking Sutykine should be aware of potential side effects, such as fatigue and gastrointestinal disturbances, which may occur as the body adjusts to the treatment. It’s important to follow your healthcare provider's instructions closely and report any unusual symptoms promptly. Regular monitoring may be required to assess the drug’s effectiveness and adjust dosages if necessary. Sutykine offers a crucial pathway in cancer therapy, aiming to improve patient outcomes through its innovative mechanism of action. By choosing Sutykine, patients are taking a proactive step in their cancer treatment journey. Always consult your doctor to ensure that Sutykine is the right choice for your specific condition and to understand its full range of benefits and precautions.
Quantity
Active Pharmaceutical Ingredient
Uses
• Sutykine 12 5 mg capsule is utilized in the treatment of Advanced Renal Cell Carcinoma (RCC), a challenging form of kidney cancer. This medication targets cancerous cells that develop in the small tubes of the kidney. By addressing this type of cancer, Sutykine 12 5 mg capsule helps manage disease progression and improves patient outcomes. It is often prescribed when other treatment options are inadequate.
• In cases of Gastrointestinal Stromal Tumor (GIST), Sutykine 12 5 mg capsule serves as a therapeutic option. GIST is a rare cancer that typically affects the digestive tract, particularly the stomach or small intestine. This medication works by targeting the specific cells involved in the tumor's growth. Clinicians may recommend Sutykine 12 5 mg capsule to patients who require alternative treatment strategies for this condition.
• Sutykine 12 5 mg capsule is also indicated for the management of Pancreatic Neuroendocrine Tumors (PNETs). These tumors originate from the hormone-producing cells in the pancreas and can present unique challenges in treatment. By utilizing Sutykine 12 5 mg capsule, healthcare providers aim to inhibit tumor growth and enhance the quality of life for patients. This medication is an important part of a comprehensive treatment plan for individuals diagnosed with PNETs.
Benefits
Sutykine 12.5 Capsule is used to treat specific forms of cancer, such as gastrointestinal stromal tumors (GISTs), renal cell carcinoma (RCC), and imatinib-resistant GIST. The advantages of using Sutykine may involve reducing the size of cancerous tumors, slowing the progression and spread of cancer, alleviating cancer-related symptoms, and potentially extending survival in some individuals.
Side Effects
Like all medicines, Sutykine 12.5 mg Capsule may cause side effects that do not require medical attention and that will disappear as your body adjusts to the medicine. Tell your doctor if they persist or if you're worried about them.
Most Common Side Effects
• Complete or Partial hair loss
• Change in hair and skin colour
• Back pain
• Stomach upset
• Dry skin
• Diarrhea
• Swollen eyes
• Tingling sensation in limbs
• Nausea and Vomiting
• Tiredness
• Muscle spasms
Common Side Effects
• Headache
• Blistered palm
• Rashes
• Sores mouth or tongue
• Bleeding
• Swollen and Painful limbs
• decreased vision
• Blood in stool
• Fast heartbeat
• Sweating
• Hypertension
• Panful urination
• Unusual weight gain
• Trouble breathing
• serious side effects
• Dizziness
• Fatal skin reaction
How To Use
You may take this medicine with or without a meal. It is recommended that you swallow the tablet whole with a full glass of water and that you do not crush, chew, or break the tablet. If you miss a dose of this medicine, take it as soon as you can. Skip the missed dose and return to your regular dosing schedule if it is almost time for your next dose. Do not take a double dose of your medicine to make up for a missed dose.
Safety Advice
• Alcohol: Drinking alcohol while taking Sutykine 12.5 mg is generally not recommended. It may increase the risk of liver damage. It is best to avoid alcohol or limit your alcohol intake while taking any medication.
• Kidney: It is safe to use Sutykine 12.5 Capsule in patients with kidney disease. No dose adjustment of Sutykine 12.5 mg Capsule is recommended. If you experience any side effects, please consult your doctor.
• Breastfeeding: It is not recommended to breastfeed while taking Sutykine 12.5 mg. Sutykine Capsule may pass into breast milk and harm the infant. If you are breastfeeding and taking Sutykine, it is important to talk to your doctor about the possible risks and benefits of continuing to breastfeed. Your doctor will be able to help you make the best decision for you and your baby's health.
• Liver: Sutykine 12.5 Capsule is safe for use in patients with mild to moderate liver disease, no dose adjustment of Sutykine 12.5 mg Capsule is recommended. The use of Sutykine is not recommended for severe liver disease patients. It is important to discuss all of your medical conditions and medications with your doctor to ensure that the treatment plan is safe and effective for you.
• Pregnancy: Use of Sutykine 12.5 mg Capsule may be unsafe during pregnancy as animal studies indicate that it may harm the developing foetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Sutykine 12.5 Capsule during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.
• Driving: Sutykine Capsule may cause dizziness, fatigue, and difficulty concentrating and coordinating, which may affect your ability to drive a vehicle safely. It is important to follow your doctor's instructions and take necessary precautions such as avoiding driving a vehicle or operating heavy machinery if you suffer from the side effects of this Sutykine.